



11- 05- 04

IFW

Attorney Docket No. 5808.04

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventors: Qaber et al. )  
Application No.: 10/774,043 )  
Filed: February 5, 2004 ) Group Art Unit: 1617  
For: BETA-SHEET MIMETICS AND )  
METHODS RELATING TO THE USE )  
THEREOF )  
Examiner: Unknown )

CERTIFICATE OF EXPRESS MAIL

"Express Mail" mailing label number: EV 329265121 US

Date of Deposit: November 4, 2004

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR § 1.10 on the date indicated above and is addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Stacey L. Stamper  
Stacey L. Stamper

11/4/04  
Date

**INFORMATION DISCLOSURE STATEMENT  
UNDER 37 CFR § 1.97(b)(3)**

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 222313-1450

Sir:

In accordance with 37 C.F.R. §§ 1.56 and 1.97 through 1.98, Applicants wish to make known to the Patent and Trademark Office the references set forth in the attached Form PTO/SB/08A. This application is a continuation and relies (under 35 U.S.C. §120) on the earlier filing date of prior Serial No. 09/960,864, filed September 21, 2001 (now abandoned); which is a continuation of Serial No. 09/501,052, filed February 9, 2000 (now U.S. Patent No. 6,372,744); which is a divisional of Serial No. 09/022,934, filed February 12, 1998 (now U.S. Patent No. 6,117,896); which claims the benefit of PCT Application No. PCT/US97/13622, filed August 5, 1997 and U.S. Provisional Application No. 60/047,067, filed May 19, 1997, and is a CIP of Serial no. 08/797,915,

filed February 10, 1997 (now abandoned); which is a CIP of Serial No. 08/692,420, filed August 5, 1996 (now abandoned).

The references listed on the attached Form PTO/SB/08A were submitted to and/or cited by the Patent and Trademark Office in these prior applications and, therefore, are not required to be provided in this application. If the Examiner wishes, copies will be provided upon request.

It is requested that the Examiner consider these documents and officially make them of record in accordance with the provisions of 37 CFR § 1.97 and Section 609 of the MPEP. By referring to the listed documents, Applicants are in no way making any admission as to prior art status of the listed documents, but are instead referring to the listed documents for the sake of full disclosure under 37 CFR § 1.56.

To the best of the undersigned person's knowledge, this Information Disclosure Statement is being submitted in accordance with 37 CFR § 1.97(b)(3), before the mailing of a first Office Action on merits.

It is believed that neither an extension of time, nor payment of any fee is required in connection with this communication. However, if an extension of time and corresponding extension fee, or any other fee is required, such an extension of time is hereby petitioned for and the Commissioner is authorized to charge any fees, or credit any overpayment, to Deposit Account No. 50-1627.

Respectfully submitted,



Andrew Gibbs  
Registration No. 52,943

Intellectual Property Department  
**Myriad Genetics, Inc.**  
(Customer No. 26698)  
320 Wakara Way  
Salt Lake City, UT 84108  
Telephone: 801-584-3600  
Fax: 801-883-3871

Date: November 4, 2004



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)			<b>Complete if Known</b>		
			Application Number	10/774,043	
			Filing Date	February 5, 2004	
			First Named Inventor	Qabar et al.	
			Art Unit	1617	
			Examiner Name	Unknown	
Sheet	1	of	4	Attorney Docket Number	5808.04

U.S. PATENT DOCUMENTS					
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
		4,307,094	12/22/1981	Hassall et al.	
		4,767,871	08/30/1988	Holmes et al.	
		4,885,023	12/05/1989	Yamaguchi et al.	
		5,180,418	01/19/1993	Pissiotas et al.	
		6,117,896	09/12/2000	Qabar et al.	
		6,372,744	04/16/2002	Qabar et al.	

FOREIGN PATENT DOCUMENTS							
Examiner Initials'	Cite No. <sup>1</sup>	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup>	Number <sup>4</sup> Kind Code <sup>5</sup> (if known)				
		CA	593525	03/01/1960	Clarke		
		EP	104484	04/04/1984	Koybayashi et al.		
		JP	59-172491	09/29/1984	Nagano et al.		
		DD	228812	10/23/1985	Meyer et al.		
		JP	01-121290	05/12/1989	Yamaguchi et al.		
		DE	3813884	11/16/1989	Dorfmeister et al.		
		EP	370955	05/03/1990	Pissiotas et al.		
		WO	93/16103	08/19/1993	Flynn et al.		
		WO	93/23403	11/25/1993	Flynn et al.		
		EP	599 444	06/01/1994	Karanewsky et al.		
		WO	95/33751	12/14/1995	Dolle et al.		
		WO	95/35308	12/28/1995	Bemis et al.		
		WO	96/19483	06/27/1996	Dimaio et al.		
		EP	743 319	11/20/1996	Robl et al.		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

<b>Substitute for form 1449A/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)			<b>Complete if Known</b>		
			Application Number	10/774,043	
			Filing Date	February 5, 2004	
			First Named Inventor	Qaber et al.	
			Art Unit	1617	
			Examiner Name	Unknown	
Sheet	2	of	4	Attorney Docket Number	5808.04

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		ADAM et al., "Determination of the Triplet Lifetimes of 1,3-Cyclopentadiyl Biradicals Derived from the Photodenitrogenation of Azoalkanes with Time-Resolved Photoacoustic Calorimetry," <i>J. Org. Chem.</i> 58: 1477-1482, 1993.	
		ASPINALL et al., "Enhanced Discrimination by Aza Dienophiles over their Olefinic Counterparts for the Diastereotopic Faces of Methyl (E,E)-5-(2', 3', 4', 6'-Tetra-O-acetyl-β-D-glucopyranosyloxy)penta-2,4-dienoate," <i>Tetrahedron Letters</i> 35(20): 3397-3400, 1994.	
		ATTWOOD et al., "The Design and Synthesis of the Angiotensin Converting Enzyme Inhibitor Cilazapril and Related Bicyclic Compounds," <i>J. Chem. Soc. Perkin Trans. 1</i> : 1011-1019, 1986.	
		BALDWIN et al., "Synthesis Of A Bicyclic γ-Lactam Dipeptide Analogue," <i>Heterocycles</i> 34(5): 903-906, 1992.	
		BAUER et al., "Mehrfach ungesättigte Radikalkationen: Regio- und Stereochemie der oxidativen Dimerisierung von Heptafulvenen," <i>Chem. Ber.</i> 117: 809-826, 1984.	
		BAYDAR et al., "Acyl Analogues of the Ene Reaction," <i>J. Chem. Soc. Chem. Comm.</i> pp. 650-652, 1976.	
		BERNABEU et al., "(2E)-4-Methoxy-2,4-pentadienamides as New Dienes in the Diels-Alder Reaction," <i>Tetrahedron Letters</i> 37(20): 3595-3598, 1996.	
		BIRD et al., "Activation of Nuclear Transcription Factor NF-κB by Interleukin-1 Is Accompanied by Casein Kinase II-mediated Phosphorylation of the p65 Subunit," <i>The Journal of Biological Chemistry</i> 272(51): 32606-32612, 1997.	
		BOYD et al., "The Chemistry of N-Substituted 3-Amino-1H-2-benzopyran-1-ones and 5-Amino-2,3-dihydrofuran-2-ones. Ene-type Reactions involving Transfer of Acyl Groups. X-Ray Crystal Structure of cis-3,4-Dihydro-4-morpholinocarbonyl-3-p-nitrophenyl-1H-2-benzopyran-1-one," <i>J. Chem Soc. Perkin Trans. 1</i> : pp. 1351-1360, 1978.	
		BUTT et al., "Transcription Factors as Drug Targets: Opportunities for Therapeutic Selectivity," <i>Gene Expression</i> 4: 319-336, 1995.	
		COLOMBO et al., "Conformationally Constrained Dipeptides: Synthesis of 7,5- and 6,5-Fused Bicyclic Lactams by Stereoselective Radical Cyclizations," <i>Tetrahedron Letters</i> 36(4): 625-628, 1995.	
		COLOMBO et al., "Synthesis of 7,5-Fused Bicyclic Lactams by Stereoselective Radical Cyclization," <i>Tetrahedron Letters</i> 35(23): 4031-4034, 1994.	
		COWLEY et al., "Regio- and Stereo-selective Intermolecular Interceptions of a Conjugated N-Acylhydrazonium Ion," <i>Tetrahedron Letters</i> 35(42): 7853-7856, 1994.	
		GOLDSCHMIDT et al., "Activation Of Electron Deficient Cycloheptatrienes By Tricarbonyliron Complexation," <i>Tetrahedron Letters</i> 31(46): 6711-6712, 1990.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)			<b>Complete if Known</b>		
			Application Number	10/774,043	
			Filing Date	February 5, 2004	
			First Named Inventor	Qaber et al.	
			Art Unit	1617	
			Examiner Name	Unknown	
Sheet	3	of	4	Attorney Docket Number	5808.04

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>2</sup>
		GRANGIER et al., "Reactivity of Nucleophilic Uracil Derivatives," <i>J. Heterocyclic Chem.</i> 31: 1707-1714, 1994.		
		HASSALL et al., "The Design and Synthesis of New Triazolo, Pyrazolo-, and Pyridazo-pyridazine Derivatives as Inhibitors of Angiotensin Converting Enzyme," <i>J. Chem. Soc. Perkin Trans. I</i> : 155-164, 1984.		
		JUNGHEIM et al., "Bicyclic Pyrazolidinones, A New Class Of Antibacterial Agent Based On The $\beta$ -Lactam Model," <i>Tetrahedron Letters</i> 28(3): 285-288, 1987.		
		LI et al., "Conformationally Restricted Peptide Mimetics: The Incorporation of 6,5-Bicyclic Lactam Ring Skeletons into Peptides," <i>J. Org. Chem.</i> 60: 8155-8170, 1995.		
		LOMBART et al., "Synthesis of Enantiopure $\alpha,\omega$ -Diamino Dicarboxylates and Azabicycloalkane Amino Acids by Claisen Condensation of $\alpha$ -[N-(Phenylfluorenyl)amino] Dicarboxylates," <i>The Journal of Organic Chemistry</i> 59(21): 6147-6149, 1994.		
		MATHEWS et al., "Active-Site Mimetic of Thrombin," <i>Acta Crystallographica Section D. Biological Crystallography</i> D51(4): 550-559, July 1, 1995.		
		MAYER et al., "A unique geometry of the active site of angiotensin-converting enzyme consistent with structure-activity studies," <i>Journal of Computer-Aided Molecular Design</i> 1: 3-16, 1987.		
		MOYNAGH et al., "Interleukin-1 activates transcription factor NF $\kappa$ B in glial cells," <i>Biochem. J.</i> 294: 343-347, 1993.		
		MUELLER et al., "Synthesis of 6,5-Fused Bicyclic Lactams as Potential Dipeptide $\beta$ -Turn Mimetics," <i>Tetrahedron Letters</i> 35(24): 4091-4092, 1994.		
		NAGAI et al., "Bicyclic Turned Dipeptide (BTD) as a $\beta$ -Turn Mimetic; its Design, Synthesis and Incorporation into Bioactive Peptides," <i>Tetrahedron</i> 49(17): 3577-3592, 1993.		
		ROBERTS et al., "Asymmetric Synthesis of Two-Residue Modules Designed for Mimicry of Beta Strands," <i>Tetrahedron Letters</i> 36(5): 691-694, 1995.		
		ROBL et al., "Dual Metalloprotease Inhibitors. 6. Incorporation of Bicyclic and Substituted Monocyclic Azepinones as Dipeptide Surrogates in Angiotensin-Converting Enzyme/Neutral Endopeptidase Inhibitors," <i>J. Med. Chem.</i> 39: 494-502, 1996.		
		ROBL, "Peptidomimetic Synthesis: Utilization of N-Acyliminium Ion Cyclization Chemistry in the Generation of 7,6- and 7,5-Fused Bicyclic Lactams," <i>Tetrahedron Letters</i> 35(3): 393-396, 1994.		
		RUBARTELLI et al., "Interleukin I $\beta$ and thioredoxin are secreted through a novel pathway of secretion," <i>Biochem. Soc. Trans.</i> 19: 255-259, 1991.		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/774,043
				Filing Date	February 5, 2004
				First Named Inventor	Qaber et al.
				Art Unit	1617
				Examiner Name	Unknown
Sheet	4	of	4	Attorney Docket Number	5808.04

[illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 35 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.